TY - JOUR
T1 - Collateral consequences of agricultural fungicides on pathogenic yeasts
T2 - a One Health perspective to tackle azole resistance
AU - Castelo-Branco, Débora
AU - Lockhart, Shawn R
AU - Chen, Yee-Chun
AU - Santos, Daniel Assis
AU - Hagen, Ferry
AU - Jane Hawkins, Nichola
AU - Lavergne, Rose-Anne
AU - Meis, Jacques
AU - Le Pape, Patrice
AU - Fabio Gadelha Rocha, Marcos
AU - Julio Costa Sidrim, José
AU - Arendrup, Maiken
AU - Morio, Florent
N1 - This article is protected by copyright. All rights reserved.
PY - 2021/12/2
Y1 - 2021/12/2
N2 - Candida and Cryptococcus affect millions of people yearly, being responsible for a wide array of clinical presentations, including life-threatening diseases. Interestingly, most human-pathogenic yeasts are not restricted to the clinical setting, as they are also ubiquitous in the environment. Recent studies raise concern regarding the potential impact of agricultural use of azoles on resistance to medical antifungals in yeasts, as previously outlined with Aspergillus fumigatus. Thus, we undertook a narrative review of the literature and provide lines of evidence suggesting that an alternative, environmental route of azole resistance, may develop in pathogenic yeasts, in addition to patient route. However, it warrants sound evidence to support that pathogenic yeasts cross border between plants, animals and humans and that environmental reservoirs may contribute to azole resistance in Candida or other yeasts for humans. As these possibilities could concern public health, we propose a road map for future studies under the One Health perspective.
AB - Candida and Cryptococcus affect millions of people yearly, being responsible for a wide array of clinical presentations, including life-threatening diseases. Interestingly, most human-pathogenic yeasts are not restricted to the clinical setting, as they are also ubiquitous in the environment. Recent studies raise concern regarding the potential impact of agricultural use of azoles on resistance to medical antifungals in yeasts, as previously outlined with Aspergillus fumigatus. Thus, we undertook a narrative review of the literature and provide lines of evidence suggesting that an alternative, environmental route of azole resistance, may develop in pathogenic yeasts, in addition to patient route. However, it warrants sound evidence to support that pathogenic yeasts cross border between plants, animals and humans and that environmental reservoirs may contribute to azole resistance in Candida or other yeasts for humans. As these possibilities could concern public health, we propose a road map for future studies under the One Health perspective.
U2 - 10.1111/myc.13404
DO - 10.1111/myc.13404
M3 - Book/Film/Article review
C2 - 34821412
JO - Mycoses
JF - Mycoses
SN - 0933-7407
ER -